RNA-binding proteins in neurological disease

Department of Neurology, University of Massachusetts Medical School, Worcester, MA, 01605, USA.
Brain research (Impact Factor: 2.84). 06/2012; 1462:1-2. DOI: 10.1016/j.brainres.2012.05.038
Source: PubMed
Download full-text


Available from: J. Paul Taylor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Considering there are no treatments for progressive forms of multiple sclerosis (MS), a comprehensive understanding of the role of neurodegeneration in the pathogenesis of MS should lead to novel therapeutic strategies to treat it. Many studies have implicated viral triggers as a cause of MS, yet no single virus has been exclusively shown to cause MS. Given this, human and animal viral models of MS are used to study its pathogenesis. One example is human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Importantly, HAM/TSP is similar clinically, pathologically, and immunologically to progressive MS. Interestingly, both MS and HAM/TSP patients were found to make antibodies to heterogeneous nuclear ribonucleoprotein (hnRNP) A1, an RNA-binding protein overexpressed in neurons. Anti-hnRNP A1 antibodies reduced neuronal firing and caused neurodegeneration in neuronal cell lines, suggesting the autoantibodies are pathogenic. Further, microarray analyses of neurons exposed to anti-hnRNP A1 antibodies revealed novel pathways of neurodegeneration related to alterations of RNA levels of the spinal paraplegia genes (SPGs). Mutations in SPGs cause hereditary spastic paraparesis, genetic disorders clinically indistinguishable from progressive MS and HAM/TSP. Thus, there is a strong association between involvement of SPGs in neurodegeneration and the clinical phenotype of progressive MS and HAM/TSP patients, who commonly develop spastic paraparesis. Taken together, these data begin to clarify mechanisms of neurodegeneration related to the clinical presentation of patients with chronic immune-mediated neurological disease of the central nervous system, which will give insights into the design of novel therapies to treat these neurological diseases.
    Full-text · Article · Jan 2012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Frontotemporal lobar degeneration (FTLD) is clinically, pathologically and genetically heterogeneous. Three major proteins are implicated in its pathogenesis. About half of cases are characterized by depositions of the microtubule associated protein, tau (FTLD-tau). In most of the remaining cases, deposits of the transactive response (TAR) DNA-binding protein with Mw of 43 kDa, known as TDP-43 (FTLD-TDP), are seen. Lastly, about 5-10 % of cases are characterized by abnormal accumulations of a third protein, fused in sarcoma (FTLD-FUS). Depending on the protein concerned, the signature accumulations can take the form of inclusion bodies (neuronal cytoplasmic inclusions and neuronal intranuclear inclusions) or dystrophic neurites, in the cerebral cortex, hippocampus and subcortex. In some instances, glial cells are also affected by inclusion body formation. In motor neurone disease (MND), TDP-43 or FUS inclusions can present within motor neurons of the brain stem and spinal cord. This present paper attempts to critically examine the role of such proteins in the pathogenesis of FTLD and MND as to whether they might exert a direct pathogenetic effect (gain of function), or simply act as relatively innocent witnesses to a more fundamental loss of function effect. We conclude that although there is strong evidence for both gain and loss of function effects in respect of each of the proteins concerned, in reality, it is likely that each is a single face of either side of the coin, and that both will play separate, though complementary, roles in driving the damage which ultimately leads to the downfall of neurons and clinical expression of disease.
    Full-text · Article · Aug 2012 · Acta Neuropathologica
  • [Show abstract] [Hide abstract]
    ABSTRACT: Frontotemporal dementia (FTD) is a nonAlzheimer's form of dementia. Onset age lies in the mid-to-late 50s. FTD affects the frontal and/or the temporal lobes and is clin-ically divided into two main categories: behavioural vari-ant (bvFTD) and language variant. FTD is characterised by heterogeneous pathology defined by pathogenic protein inclusions: microtubule-associated protein tau (MAPT), ubiquitin/transactive responses (TAR) deoxyribonucleic acid (DNA)-binding protein 43 (TDP)-43, fused in sarcoma (FUS) and p62. MAPT, progranulin (PGRN) and, recently, C9orf72 genes represent the three main genetic markers associated with FTD. In addition, genetic variability in TDP-43, charged multivesicular body protein 2B (CHMP2B), valosin-containing protein (VCP), FUS and TMEM106B genes contribute to 45% of cases. Research tools such as genome-wide association studies and exome and genome sequencing hold promise to further uncover the genetic underpinnings of this complex disorder.
    No preview · Article · May 2013 · Wiley interdisciplinary reviews. Cognitive science
Show more